The findings support continued development of the toothpaste for children

A recent study found that a specially formulated toothpaste can be successfully used for oral mucosal immunotherapy in adults with peanut allergy. The abstract for the study was presented by the author, allergist William Berger, MD, at the Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in November.

The study included 32 adults with peanut allergy in a 3:1 ratio of treatment to control. Over the course of the 48-week trial, participants received either an escalating dose of peanut toothpaste or a placebo. Safety was monitored during the up-dosing and maintenance phases, exploratory biomarkers were evaluated, and oral food challenges were conducted.

All subjects in the treatment group consistently tolerated the maximum dose of peanut toothpaste. No moderate or severe systemic reactions were observed. Non-systemic adverse reactions were mostly local (oral itching), mild and transient. Adherence to treatment was 97% and exploratory biomarkers were consistent with an immunologic response.

The results of the study suggest that oral mucosal immunotherapy is a safe and convenient option for individuals with food allergies. The findings also support continued development of the peanut toothpaste in the pediatric population.

Berger, W. (2023). A Randomized, Placebo-Controlled Phase 1 Safety Study of OMIT in Adults with Peanut Allergy. Annals of Allergy, Asthma & Immunology, 131(5), Supplement 2, S231.

Join us

Sign up to become a member of the INC and discover the benefits of INC membership. Or subscribe and have access to our magazine, industry newsletters and industry directory.

Privacy Preference Center